London, Nov 7 (IANS) Danish pharma giant Novo Nordisk has said it is aware of at least 10 deaths and 100 hospitalisations linked to compounded versions of semaglutide — the active ingredient in popular diabetes and obesity drugs Ozempic and Wegovy. The company’s chief financial officer Karsten Munk Knudsen said that the deaths and hospitalisations, recorded in the last two years, were reported in the US Food and Drug Administration’s (FDA) adverse event reporting database for semaglutide. While the reports are submitted by doctors, patients, drugmakers, and others, they often lack key details. These also do not establish the cause of death. According to the US FDA, a drug may be compounded f
Hence then, the article about aware of 10 deaths linked to compounded semaglutide intake novo nordisk was published today ( ) and is available onNews room odisha ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Aware of 10 deaths linked to compounded semaglutide intake: Novo Nordisk )